Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review article

SARS-CoV-2 variants, a still unfinished story\textsuperscript{\textdagger}

M. Pérez-Abeledo\textsuperscript{a}, J.C. Sanz Moreno\textsuperscript{a,b,}\textsuperscript{*}

\textsuperscript{a} Unidad de Microbiología Clínica, Laboratorio Regional de Salud Pública de la Comunidad de Madrid, Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Madrid, Spain

\textsuperscript{b} Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

\textbf{Abstract}

Mutations in the SARS-CoV-2 genome can affect the gene encoding the Spike (S) antigen, which interacts with the host cell specific receptor, selecting mutant variants with changes in their infective capacity, pathogenic potential and resistance to neutralizing antibodies. The nomenclature to design the variants uses a colloquial form referred to the country or place of detection, a code from the "Fangolin" database and one from the "Nextstrain" page. New variants that have spread include the British B.1.1.7 (20I/501Y.V1), the South African B.1.351 (20H/501.V2), the Brazilian P.1 (20J/501Y.V3), the Californians B.1.427 B.1.429 (20C/S:452R) and the most recent, the Indian B.1.617 (VUI-21APR-01).

The gold standard for the identification of the variants is whole genome sequencing. However, real-time PCR techniques have already been developed for the detection of specific mutations that can facilitate their presumptive identification.

The impact of these variants on global vaccination programs has raised concern. It is generally thought that, since the response evoked by the vaccine against the S antigen is directed at the entire protein and the mutations only affect specific regions, the escape effect of the vaccine antibodies will be limited. Among the future strategies proposed for immuno-protection, the increase in the number of doses, the alternation of vaccines and the development of specific vaccines against different variants has been suggested.

© 2021 Published by Elsevier España, S.L.U.

\textbf{Palabras clave:}

SARS-CoV-2

Variantes

\textbf{Resumen}

Las mutaciones en el genoma de SARS-CoV-2 pueden afectar al gen que codifica el antígeno espícular (S), que interactúa con el receptor específico de la célula huésped, seleccionando variantes mutantes con alteraciones en su capacidad infectiva, potencial patógeno y resistencia a los anticuerpos neutralizantes. En la nomenclatura de las variantes se utiliza...

DOI of original article: https://doi.org/10.1016/j.vacun.2021.06.003.

\textsuperscript* Please cite this article as: Pérez-Abeledo M, Sanz Moreno JC. Variantes de SARS-CoV-2, una historia todavía inacabada. Vacunas. 2021;22:167–173.

\textsuperscript* Corresponding author.

E-mail address: juan.sanz@salud.madrid.org (J.C. Sanz Moreno).

2445-1460© 2021 Published by Elsevier España, S.L.U.
Introduction

Although the SARS-CoV-2 genome appears relatively stable, this type of single-stranded RNA virus accumulates an estimated mutation rate of around $10^{-6}$–$10^{-4}$ per replicative cycle. These mutations can affect the interaction of the spike antigen (S) with the host cellular receptor (angiotensin-converting enzyme 2 [ACE2]), affecting susceptibility to immune response, the aggressiveness of the infection, and/or the transmission capacity of the virus. Thus, some mutations may confer evolutionary advantages that favour the selection of certain lineages or variants.¹

Variants can appear from genetic deletions (characterised by the loss of a portion of the nucleic acid sequence), synonymous mutations (also known as silent or nonsense mutations, which do not cause changes in amino acid synthesis) or non-synonymous mutations (associated with a change in amino acid coding). The latter are the most relevant functionally. Mutations that are termed “escape” subsequently expand under selective immunological pressure that limits, but does not eliminate, replication.² Different variants have emerged in recent months that are co-circulating worldwide, and new variants are predicted to continue to emerge in the future. Table 1 summarises the main SARS-COV-2 variants currently circulating.

Nomenclature

Although the terms strain and variant are usually used synonymously after mutations have occurred, in a pure sense they should cover the induction or otherwise of changes in the behaviour of the virus.³ However, these terms will be used interchangeably in this text. The nomenclature of the different variants of SARS-CoV-2 that have gradually emerged uses a “‘coloquial” form that usually refers to the country or place where the variant was detected (British strain), a code from the Pangolin database⁴ (B.1.1.7), and one based on the Nextstrain page⁵ (20I/501Y.V1). This multiple system can often lead to confusion. To provide information, the World Health Organisa-tion (WHO) very recently adopted a simpler system based on letters of the Greek alphabet to denote the various variants.⁶ Table 2 shows the new nomenclature for the different variants.

The different mutations associated with changes in amino acids are named with an alpha-numeric key that indicates, firstly, the code of a capital letter of the amino acid that has been replaced, a number that refers to the position of the change and finally the capital letter corresponding to the code of the new amino acid. Thus, for example, the mutation N501Y indicates that the amino acid asparagine (N) has been replaced by a tyrosine (Y) at position 501.

Classification of the SARS-CoV-2 variants

The different SARS-CoV-2 variants have been classified according to their level of importance⁷:

Variants of Interest (VOI) are those that have been associated with changes to receptor binding, reduced neutralisation by antibodies generated against previous natural infection or vaccination, reduced efficacy of treatments, potential diagnostic impact, or predicted increase in transmissibility and/or disease severity, with clusters of cases and outbreaks, but with limited prevalence in other countries. Examples of variants of interest are B.1.525 (20A/S:484K), B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.617 (20A), B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), B.1.617.3 (20A), and P.2 (20).⁷

Variants of Concern (VOC) include variants where there is evidence of an increase in transmissibility, severity, reduction in neutralisation by natural antibodies or those generated by vaccination, reduced effectiveness of treatments or diagnostic test failures. Examples of variants of concern are the British B.1.1.7 (20I/501Y.V1), the South African B.1.351 (20H/501.V2), the Brazilian P1 (20I/501Y.V3), the Californian B.1.427 (20C/S:452R) and the Californian B.1.429 (20C/S:452R).⁷

Variants of High Consequence (VOC) include those for which there is clear evidence that prevention and therapeutic measures have significantly reduced effectiveness relative to previously circulating variants. Fortunately, at present, there are no known SARS-CoV-2 variants that fall into this category.⁷
### Table 1 – Main SARS-COV-2 variants currently circulating[^7]

| Colloquial name | Wild type | British | South African | Brazilian | Californian | Californian | Indian |
|-----------------|-----------|---------|---------------|-----------|------------|------------|--------|
| Pangolin lineage name | D614G | B.1.1.7 | 20I/S:501Y.V1 | 20H/S:501Y.V2 | 20V/S:501Y.V2 | 20V/S:452R | B.1.617 |
| Name | | 20I/S:501Y.V1 | 20H/S:501Y.V2 | 20V/S:501Y.V2 | 20V/S:452R | 20A | 20A |
| Nextstrain | | 20I/S:501Y.V1 | 20H/S:501Y.V2 | 20V/S:501Y.V2 | 20V/S:452R | 20A | 20A |
| Mutations | | | | | | 284K, 225V | 284K, 225V |
| Associated characteristics | | 50% increase in transmission capacity. | Reduction in convalescent and post-vaccination serum neutralisation. | 20% increase in transmission capacity. | Reduction in convalescent and post-vaccination serum neutralisation. | 20% increase in transmission capacity. | Pending specification at the time of drafting this text. |

[^7]: Variants of concern and variants of interest.

---

### Table 2 – WHO nomenclature, proposed for naming variants of concern and variants of interest.

| WHO level | Pangolin lineage | Nextstrain clade | GISAID clade/lineage[^a] |
|-----------|------------------|------------------|--------------------------|
| Variants of concern | | | |
| Alpha | B.1.1.7 | 20I/S:501Y.V1 | GRY (formerly GR/501Y.V1) |
| Beta | B.1.351 | 20H/S:501Y.V2 | GR/S:501Y.V2 |
| Gamma | P.1 | 20I/S:501Y.V3 | GR/S:501Y.V3 |
| Delta | B.1.617.2 | 21A/S:478K | GR/S:478K |
| Epsilon | B.1.427/B.1.429 | 20C/S:452R | GH/S:452R |
| Zeta | P.2 | 20B/S:484K | GR/S:484K |
| Eta | B.1.525 | 20A/S:484K | G/484K.V3 |
| Theta | P.3 | 20A/S:265C | GR |
| Iota | B.1.526 | 20C/S:484K | GH |
| Kappa | B.1.617.1 | 21A/S:154K | G/452R.V3 |

[^a]: GISAID: Global initiative on sharing all influenza data.
The European Centre for Disease Prevention and Control (ECDC) envisages an additional category, termed variants under monitoring, for those with similar properties to variants of concern, but for which there is only preliminary scientific evidence. The mutations, harbours This and A combination of the D614G and N501Y mutations with the K417N, E484K mutations. Unlike the British strain, it does not carry the 69/70 deletion. The N501Y mutation in the South African variant, although also present in the UK variant, appears to be phylogenetically distinct. There is uncertainty as to whether it is associated with greater severity or worse prognosis. Compared to the wild type strain, it appears to be markedly more resistant to neutralisation by serum from convalescent or vaccinated subjects.

**Wild type strain**

The original strain that started the COVID-19 pandemic in 2020 carried the 484E mutation. This mutation is located in the epitope of the dominant region encoding the S protein. Between January and February 2020, a SARS-CoV-2 variant emerged with a D614G substitution in the gene encoding the S protein. The original strain had the 614D precursor. This D614G mutation in the wild type strain enhanced its ability to drive the pandemic. Over a period of several months the D614G mutant strain replaced the strain initially identified in China and by June 2020 it had become dominant. This strain, compared to its precursor, showed increased infectivity and transmissibility. However, it was not associated with increased severity, impaired effectiveness of laboratory diagnostic tests, decreased neutralising capacity of antibodies or reduced therapeutically effectiveness.

**British variant**

The variant termed the British B.1.1.7 (20I/501Y.V1) was detected at the end of 2020 in the UK and has rapidly spread to many countries, often supplanting the original wild type strain. It has more than 20 mutations, excluding those not associated with changes in amino acids, almost half of which affect the S antigen coding regions (the main target of neutralising antibodies). This variant maintains the D614G mutation and also shows the N501Y mutation that seems to increase the interaction of the S protein with the ACE2 receptor as it affects the receptor binding domain (RBD). In addition, it has the 69/70 deletion. This deletion may decrease the diagnostic sensitivity of certain PCR tests that target the gene coding for the S antigen. However, since most PCR techniques combine multiple targets, this may not be too problematic. These molecular changes seem not to impact the performance of rapid antigen tests. This variant has been associated with increased transmissibility and severity. Although the increased clinical severity of this and other variants may be questionable, the increased mortality reported for this strain is 4.1 deaths per 1000 cases detected (compared to that of previously circulating strains estimated at 2.5 per 1000 cases) and it shows relative resistance to neutralisation by monoclonal antibodies to the S antigen. However, it is not more resistant to plasma from individuals exposed to natural infection or following vaccination.

**South African variant**

The B.1.351 variant (20H/501.V2), which may have appeared a few months earlier, was reported in South Africa in December 2020. This variant, which emerged independently of B.1.1.7, harbours several non-synonymous mutations and a deletion that mostly affects the S protein. It combines the D614G and N501Y mutations with the K417N, E484K mutations. Unlike the British strain, it does not carry the 69/70 deletion. The N501Y mutation in the South African variant, although also present in the UK variant, appears to be phylogenetically distinct. There is uncertainty as to whether it is associated with greater severity or worse prognosis. Compared to the wild type strain, it appears to be markedly more resistant to neutralisation by serum from convalescent or vaccinated subjects.

**Brazilian variant**

The Brazilian variant P.1 (B.1.1.28.1, 20I/501Y.V3) was detected in Japan from travellers from Brazil. It contains several mutations, including three affecting the S protein. The E484K mutation, shared by both the Brazilian and South African variants, has triggered alarm due to its possible link to some immune evasiveness. Both variants have been associated with increased transmissibility and a higher reinfection rate. The other two mutations of this variant that affect the S protein are K417T and N501Y. A way of distinguishing the South African variant from the Brazilian variant is that the Brazilian variant lacks the K417N mutation.

**B.1.1.7 variant with E484K mutation**

The detection of the E484K mutation in B.1.1.7. sequences has also raised concerns about a loss of vaccine efficacy, due to its combination with the other mutations of the British variant.

**Californian variant**

Other emerging variants include strain B.1.429 (20C/S:452R) and B.1.427 (20C/S:452R) circulating in California. The B.1.429 variant, which has the L452R, D614G and W152C mutations, among others, has spread rapidly in the US and other countries, and is less susceptible to neutralisation by serum from convalescent or vaccinated subjects. These variants have been classified as variants of concern by the CDC (Centres for Disease Control and Prevention), whereas the WHO considers them only variants of interest.

**Indian variant**

More recently, there has been widespread alarm about the emergence and spread in India of the new variant B.1.617, also known as VUI (Variant Under Investigation)-21APR-01, and 20A according to “Nextstrain”. It is considered a variant of interest for the time being. Some media are reporting this strain as a “double mutant” because it combines the L452R mutations of the California strain with the E484Q mutation. The term “double mutant” is meaningless considering that the other SARS-CoV-2 variants also carry several mutations simultaneously. Other related lineages are B.1.617.1 (20A/S:154K), B.1.617.2 (20A/S:478K), and B.1.617.3 (20A). These three lineages have the L452R muta-
Markers of the mutations that enable differentiating between the main variants currently circulating.

| Variant                        | 484E | E484K | 501N | N501Y | K417N | L452R | E484Q |
|-------------------------------|------|-------|------|-------|-------|-------|-------|
| Wild type                     |      |       | +    | +     | +     | +     | +     |
| British B.1.1.7               | +    | –/+   | +    | +     | +     | +     | +     |
| South African B.1.351         |      |       |      |       |       |       | +     |
| Brazilian P1                  | +    | +     | +    |       | +     | +     | +     |
| Californian B.1.427 y B.1.429 |      |       |      |       |       |       | +     |
| Indian B.1.617, B.1.617.1 and B.1.617.3 |      |       |      |       |       |       | +     |

Vaccination and variants

The impact of these variants on global vaccination programmes has raised concerns and the development of markers that correlate vaccine and protection is considered a priority. As we mention above, it has been suggested that the new variants could escape the immune response more easily. In general, it is considered that since the vaccine-evoked response to the S antigen targets the entire protein and mutations only affect specific regions, it does not appear that the new variants can completely evade the action generated after vaccination. The results of immunisation in Israel are encouraging in this regard, where the British variant is predominant. Preliminary trials have also shown an acceptable vaccine-induced neutralising response to different variants. The main SARS-CoV-2 vaccines include messenger RNA vaccines (mRNA-1273; Moderna and BNT162b2; Pfizer), vector vaccines (ChAdOx1; AstraZeneca and Ad26.COV2.S; Janssen), and the protein subunit vaccine NVX-CoV2373 (Novavax). Messenger RNA vaccines (mRNA-1273; Moderna and BNT162b2; Pfizer), vector vaccines (ChAdOx1; AstraZeneca and Ad26.COV2. Messenger RNA vaccines (mRNA-1273; Moderna and BNT162b2; Pfizer) appear to show only slightly lower efficacy against the UK variant. However, their neutralising capacity is significantly reduced against the South African variants and to a lesser extent against the Brazilian variant (given the high titre of antibodies generated for the latter variant, the decreased neutralising activity seems to have a lower impact than for the South African variant). It has been suggested recently that, although the Indian B.1.617.1 variant is also more resistant to neutralisation, the Moderna and Pfizer messenger RNA vaccines may well retain their ability to protect against it. The vector vaccine ChAdOx1 (AstraZeneca), although it may show a limited loss of activity against the British variant, maintains acceptable effectiveness against it. However, the efficacy of this vaccine against the South African variant seems to have been significantly reduced, and its use in certain countries with a high prevalence of infection by this variant has been questioned. This vector vaccine, despite producing an antibody response with a reduced neutralising capacity against the Indian B.1.617.1 variant, appears to maintain efficacy that limits the severity and mortality of the infection. The vector vaccine Ad26.COV2.S (Janssen) shows less than 60% efficacy for protection against moderate/severe disease caused by the South African strain. The protein subunit vaccine NVX-CoV2373 (Novavax) is more than 80% effective against the British variant but less than 50% effective against the South African variant. The Californian variants may behave in a very similar way to the British variant towards the vaccines.

Existing data suggest that beyond the humoral immune response, the cellular response is capable of recognising the new variants of SARS-CoV-2. Thus, in addition to the production of specific antibodies, the vaccines could lead to the induction of a cellular response (helper T cells and cytotoxic T cells). The T-dependent immune response against the S protein of SARS-CoV-2 is characterised by high levels of interferon-gamma (IFN-γ) that can be detected by interferon-gamma release assays (IGRAs). These may be adjunct assays to determine immunostatus in the current pandemic.

Diagnosis of variants

In addition to the major clinical-epidemiological implications, a secondary consequence of the emergence of mutant strains is reduced performance of certain in vitro diagnostic tests. Whole genome sequencing methods are the gold standard for identifying SARS-CoV-2 variants. However, alternative, simpler and faster procedures based on real-time PCR techniques to detect specific mutations have recently been developed for this purpose. Certain combinations of mutant markers enable the main variants to be differentiated. The combination 484E and 501N identifies the wild type strain. The combination 484E and 501Y identifies the British strain. The 484K and 501Y combination occurs concomitantly in the Brazilian and South African variants, but the latter also carries the 417N mutation. The Californian variants contain the L452R mutation. The new Indian variants B.1.617, B.1.617.1 and B.1.617.3 carry the latter mutation together with E484Q. Table 3 shows the mutation markers that distinguish between the most important variants.

Table 3 shows the mutation markers that distinguish between the most important variants.
Conclusions

The mass vaccination that has begun in recent months may mark the beginning of the end of the current COVID-19 pandemic. However, it is foreseeable that new variants of the virus will continue to appear in the near future. This means that mutations must be monitored to adapt the relevant Public Health measures. Potential new emerging strains may entail changes in terms of their infectious capacity, clinical evolution, prognosis, and vaccine effectiveness. In the worst-case scenario, we should be vigilant for the potential and feared emergence of highly significant variants (as yet not identified). For the time being, standard preventive measures to reduce transmission, based on limiting interpersonal contact and maintaining safe social distances, remain in place. Certain vaccines retain their protective efficacy against new variants and thus their extensive use can be highly successful.

To avoid the possibility of selection of vaccine escape variants, it is recommended that preparations be used that generate elevated levels of antibodies with high neutralising activity after only one dose and, for vaccines that require two doses, not to prolong for too long the interval between the first and second dose. Increasing the number of doses, alternating vaccines, and developing monovalent and polyvalent vaccines against different variants have been suggested as future strategies proposed for immunoprotection.

Funding

The authors declare that they have received no funding for this study.

Conflict of interests

The authors have no conflict of interests to declare.

REFERENCES

1. Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immuno Rev. 2020;296:205–19, http://dx.doi.org/10.1111/imr.12897.
2. Moore JP, Offit PA. SARS-CoV-2 vaccines and the growing threat of viral variants. JAMA. 2021;325:821–2, http://dx.doi.org/10.1001/jama.2021.1114.
3. Gamero-de-Luna EJ, Gamero-Estévez E. Mutaciones, variantes y cepas de SARS-CoV-2. Semergen. 2021;47:208–9, http://dx.doi.org/10.1016/j.semergen.2021.01.001.
4. PANGO Lineages: Latest epidemiological lineages of SARS-CoV-2: https://cov-lineages.org/.
5. Nextstrain SARS-CoV-2 resources: https://nextstrain.org/sars-cov-2.
6. World Health Organization (WHO) Tracking SARS-CoV-2 variants [Accessed 3 Jun 2021].
7. Centers for Disease Control and Prevention (CDC) SARS-CoV-2 Variant Classifications and Definitions [Accessed 2 June 2021]. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html.
8. European Centre for Disease Prevention and Control (ECDC) SARS-CoV-2 variants of concern as of 24 May 2021 [Accessed 2 Jun 2021].
9. Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, et al. SARS-CoV-2 S01Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184:2962–71, http://dx.doi.org/10.1016/j.cell.2021.02.042.
10. World Heart Organization (WHO) SARS-CoV-2 Variants Disease Outbreak News 31 December 2020 [Accessed 24 May 2021]. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/.
11. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–38, http://dx.doi.org/10.1056/NEJMoa2028436.
12. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116–21, http://dx.doi.org/10.1038/s41586-020-2895-3.
13. Walensky RF, Falke HT, Fauci AS. SARS-CoV-2 variants of concern in the united states-challenges and opportunities. JAMA. 2021;325:1037–8, http://dx.doi.org/10.1001/jama.2021.2294.
14. GTM. informe del Grupo de Trabajo Multidisciplinar (GTM) sobre variantes del sars-cov-2 e implicaciones en los programas de vacunación global frente A COVID-19 [Accessed 24 May 2021]. https://www.ciencia.gob.es/site-web/Ministerio/Coronavirus/informes-cientificos.html.
15. Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants-tackling a moving target. JAMA. 2021;325:1261–2, http://dx.doi.org/10.1001/jama.2021.2088.
16. Centers for Disease Control and Prevention (CDC). Emerging SARS-CoV-2 Variants. [Accessed 24 May 2021].
17. Burki T. Understanding variants of SARS-CoV-2. Lancet. 2021;397:462, http://dx.doi.org/10.1016/S0140-6736(21)00298-1.
18. Challen R, Brooks-Pollock E, Retail JM, Dynel I. Tsanueva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579, http://dx.doi.org/10.1136/bmj.n579.
19. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–5, http://dx.doi.org/10.1038/s41586-021-03398-2.
20. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:2348–61, http://dx.doi.org/10.1016/j.cell.2021.02.037.
21. Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W, et al. Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. N Engl J Med. 2021, http://dx.doi.org/10.1056/NEJMct2103740.
22. Karim SSA. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Lancet. 2021;397:1263–4, http://dx.doi.org/10.1016/S0140-6736(21)00468-2.
23.Tookey OTR, Harvey KN, Bird PW, Tang JW. Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK. J Infect. 2021;82:e23–4, http://dx.doi.org/10.1016/j.jinf.2021.01.025.
24. Karim SSA, de Oliveira T. New SARS-CoV-2 variants - clinical, public health, and vaccine implications. N Engl J Med. 2021;384:1866–8, http://dx.doi.org/10.1056/NEJMct2100352.
25. Zhang W, Davis BD, Chen SS, Sinclair Martinez JM, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA. 2021;325:1324–6, http://dx.doi.org/10.1001/jama.2021.1612.
26. PANGO. Lineage B.1.617 [Accessed 24 May 2021]. https://cov-lineages.org/lineages/lineage_B.1.617.html.
27. GOV.UK. Variants: distribution of cases data. 20 May 2021. Public Health England. [Accessed 24 May 2021].
28. Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin Infect Dis. 2021;ciab411, http://dx.doi.org/10.1093/cid/ciab411.

29. Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2—what do they mean? JAMA. 2021;325:529–31, http://dx.doi.org/10.1001/jama.2020.27124.

30. Gómez CE, Perdigueró B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (Basel). 2021;9:243, http://dx.doi.org/10.3390/vaccines9030243.

31. Lustig Y, Nemét I, Klier L, Zuckerman N, Yishai R, Alroy-Preis S, et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2. N Engl J Med. 2021, http://dx.doi.org/10.1056/NEJMc2104036.

32. Wu K, Werner AP, Moliva JJ, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv [Preprint]. 2021, http://dx.doi.org/10.1101/2021.01.25.427948.

33. Reina J, Fraile-Ribot P. Impacto de las variantes genéticas de la espícula en las vacunas frente al SARS-CoV-2. Vaccinas. 2021, http://dx.doi.org/10.1016/j.vacun.2021.04.001.

34. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv [Preprint]. 2021, http://dx.doi.org/10.1101/2021.05.09.443299.

35. Yadav PD, Sapkal GN, Abraham P, Deshpande G, Nyayanit DA, Patil DY, et al. Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1. Clin Infect Dis. 2021, http://dx.doi.org/10.1093/cid/ciab483.

36. Redd AD, Nardin A, Kared H, Bloch EM, Pekosz A, Laeyendecker O, et al. CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. medRxiv [Preprint]. 2021, http://dx.doi.org/10.1101/2021.02.11.21251585.

37. Petrone L, Petruccio E, Vanini V, Cuzzi G, Najafi Fard S, Alonzi T, et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021;27:286, http://dx.doi.org/10.1016/j.cmi.2020.09.051.

38. Murugesan K, Jagannathan P, Pham TD, Pandey S, Bonilla HF, Jacobson K, et al. Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response. Clin Infect Dis. 2020;ciaa1537, http://dx.doi.org/10.1093/cid/ciaa1537.

39. FDA. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests [Accessed 24 May 2021]. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests.

40. European Centre for Disease Prevention and Control. Methods for the detection and identification of SARS-CoV-2 variants. WHO [Accessed 24 May 2021]. https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants.pdf.

41. Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, et al. Rapid detection of SARS-CoV-2 variants of concern, including B.1.1.28/P.1, in British Columbia, Canada. Emerg Infect Dis. 2021;27:1673–6, http://dx.doi.org/10.3201/eid2706.210532.

42. Tang JW, Toovey OTR, Harvey KN, Hui DDS. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J Infect. 2021;82:e8–10, http://dx.doi.org/10.1016/j.jinf.2021.01.007.

43. Bhan L, Gao F, Zhang J, He Q, Mao Q, Xu M, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021;1:9, http://dx.doi.org/10.1080/14760584.2021.1903879.